We are live on ! Find out more
NFGH

Nan Fung Group Holdings Portfolio holdings

AUM $121M
1-Year Est. Return 56.89%
This Fund
S&P 500
This Quarter Est. Return
+4.35%
1 Year Est. Return
+56.89%
3 Year Est. Return
+244.35%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$117M
AUM Growth
+$850K
Cap. Flow
+$4.42M
Cap. Flow %
3.78%
Top 10 Hldgs %
62.08%
Holding
41
New
3
Increased
8
Reduced
2
Closed
6

Top Buys

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$4.99M
2
RXRX icon
Recursion Pharmaceuticals
RXRX
+$4.47M
3
RBRK icon
Rubrik
RBRK
+$1.2M
4
TRML
Tourmaline Bio
TRML
+$1.01M
5
KYMR icon
Kymera Therapeutics
KYMR
+$903K

Top Sells

Rank Stock Value
1
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$5.35M
2
EXAI
Exscientia Plc American Depositary Shares
EXAI
+$4.2M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$760K
4
ONC
BeOne Medicines Ltd
ONC
+$618K
5
INCY icon
Incyte
INCY
+$499K

Sector Composition

Rank Sector Weight
1 Healthcare 98.3%
2 Technology 1.36%
3 Materials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ILMN icon
1
Illumina
ILMN
$31B
$15.9M 13.62%
119,196
– –
HRMY icon
2
Harmony Biosciences
HRMY
$2.08B
$12.7M 10.85%
368,665
– –
OCS icon
3
Oculis Holding
OCS
$677M
$7.42M 6.34%
436,378
– –
VRNA
4
DELISTED
Verona Pharma
VRNA
$6.18M 5.28%
+133,040
New +$4.99M
ZLAB icon
5
Zai Lab
ZLAB
$2.06B
$6.15M 5.26%
235,000
– –
MIRM icon
6
Mirum Pharmaceuticals
MIRM
$6.87B
$5.18M 4.43%
125,330
+19,230
+18% +$801K
MRUS
7
DELISTED
Merus
MRUS
$5.05M 4.32%
120,038
– –
GERN icon
8
Geron
GERN
$860M
$4.86M 4.16%
1,373,550
– –
INCY icon
9
Incyte
INCY
$24.9B
$4.63M 3.96%
67,022
-7,000
-9% -$499K
RXRX icon
10
Recursion Pharmaceuticals
RXRX
$1.61B
$4.49M 3.84%
+664,610
New +$4.47M
XENE icon
11
Xenon Pharmaceuticals
XENE
$6.2B
$4.18M 3.58%
106,680
– –
REPL icon
12
Replimune Group
REPL
$455M
$3.9M 3.33%
321,746
+33,900
+12% +$412K
TRML
13
DELISTED
Tourmaline Bio
TRML
$3.79M 3.25%
187,090
+40,290
+27% +$1.01M
ONC
14
BeOne Medicines Ltd
ONC
$33.4B
$3.69M 3.16%
19,997
-3,025
-13% -$618K
SLNO
15
DELISTED
Soleno Therapeutics
SLNO
$3.58M 3.06%
79,650
+15,700
+25% +$813K
MDGL icon
16
Madrigal Pharmaceuticals
MDGL
$11.4B
$3.43M 2.94%
11,122
+1,360
+14% +$383K
LAB icon
17
Standard BioTools
LAB
$351M
$3.3M 2.82%
1,883,179
– –
RYTM icon
18
Rhythm Pharmaceuticals
RYTM
$7.25B
$2.75M 2.35%
49,120
– –
EXEL icon
19
Exelixis
EXEL
$14.1B
$2.14M 1.83%
64,200
– –
ACAD icon
20
Acadia Pharmaceuticals
ACAD
$4.55B
$1.89M 1.62%
102,984
– –
ASND icon
21
Ascendis Pharma A/S
ASND
$16.5B
$1.87M 1.6%
13,600
– –
RBRK icon
22
Rubrik
RBRK
$14.7B
$1.59M 1.36%
+24,338
New +$1.2M
KALV
23
DELISTED
KalVista Pharmaceuticals
KALV
$1.31M 1.12%
154,522
– –
KYMR icon
24
Kymera Therapeutics
KYMR
$8.8B
$1.24M 1.06%
30,875
+20,000
+184% +$903K
BCYC
25
Bicycle Therapeutics
BCYC
$280M
$965K 0.83%
68,943
+37,358
+118% +$801K
1
2

Similar funds

TCM
TT Capital Management Coto De Caza, California $121M AUM 1.94% 1-Year Est. Return
MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
CCM
Candelo Capital Management New York $121M AUM 113.39% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Nan Fung Group Holdings's Q4 2024 Portfolio in Review

As of Q4 2024, Nan Fung Group Holdings held 41 positions worth $117M, up 0.73% from $116M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Nan Fung Group Holdings deployed $4.42M of net new capital in Q4 2024, opening 3 new positions and adding to 8 existing holdings. Its largest new stake was Verona Pharma: 133,040 shares worth $6.18M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Technology and Materials.

On the sell side, the largest reduction was BeOne Medicines Ltd, an estimated $618K trimmed.

  • Nan Fung Group Holdings's largest Q4 2024 buy was Verona Pharma: 133,040 shares worth $6.18M.
  • Nan Fung Group Holdings added most to Tourmaline Bio in Q4 2024, an estimated $1.01M increase.
  • Nan Fung Group Holdings's biggest Q4 2024 reduction was BeOne Medicines Ltd, cutting an estimated $618K.
  • Nan Fung Group Holdings fully exited Longboard Pharmaceuticals, Inc. Common Stock in Q4 2024, selling an estimated $5.35M.
  • Nan Fung Group Holdings's ten largest holdings make up 62% of its $117M portfolio in Q4 2024.
  • Nan Fung Group Holdings opened 3 new positions and closed 6 in Q4 2024.
  • Nan Fung Group Holdings's portfolio value rose 0.73% quarter-over-quarter to $117M.

Based on Nan Fung Group Holdings's 13F filing for Q4 2024, filed 13 Feb 2025.